To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects
NCT02063230
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumors
Interventions
DRUG:
Selumetinib 50mg
DRUG:
Selumetinib 25mg
Sponsor
AstraZeneca